Validity of Enzyme-Linked Immunosorbent Assay (ELISA) as a correlate of protection of meningococcal C conjugated vaccine in adolescents with HIV infection
Author(s) -
Bertolini Daniela Vinhas,
Costa Luciana Scarlazzari,
de Castro Bruno Stuart,
Pernichelli Tadeu,
van der Heijden Inneke Marie,
Costa Silvia Figueiredo,
Sato Helena Keiko,
de Sousa Marques Heloisa Helena
Publication year - 2020
Publication title -
journal of vaccines and immunology
Language(s) - English
Resource type - Journals
ISSN - 2640-7590
DOI - 10.17352/jvi.000028
Subject(s) - virology , meningococcal vaccine , human immunodeficiency virus (hiv) , antibody , conjugated system , enzyme , medicine , immunology , microbiology and biotechnology , biology , chemistry , immunization , biochemistry , organic chemistry , polymer
The immunological response to meningococcal C conjugated vaccine can be evaluated by two different tests: the serum bactericidal antibody assay (SBA), which evaluates the qualitative bactericidal capacity of the antibodies, and the Enzyme-Linked Immunosorbent Assay (ELISA), which quantifies the specific serogroup C meningococcal immunoglobulin-G. Incompatibilities between the results of both tests have been reported. Technically, ELISA is simpler, safer, and easier to reproduce when compared to the SBA; thus, an assessment of the validity of ELISA as a protective correlate compared to the SBA gold standard should be performed. This study tested the validity of ELISA for the evaluation of the protective response to the C meningococcal conjugate vaccine in adolescents with HIV compared with the gold standard SBA, to evaluate the reliability of ELISA to infer the protection of the individual.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom